GO:1901558 response to metformin: Cellular Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901558 (response to metformin) describes any cellular or organismal process that changes state or activity in response to a metformin stimulus.
• Metformin is a first-line antidiabetic drug that also impacts cancer, inflammation, viral infections, and immune responses through multiple molecular pathways [1,4,5,7].
• Key genes and proteins involved in the response to metformin include AMPK (PRKAA1/PRKAA2), STK11 (LKB1), and downstream effectors such as mTOR, ACC, and S6K [1,4].
• Metformin modulates mitochondrial respiration, activates AMPK, inhibits mTOR signaling, and alters gene expression, making it a valuable tool for studying metabolic and stress responses [1,4,7].
• Dysregulation of metformin-responsive pathways is linked to diabetes, cancer, cardiovascular disease, and severe viral infections such as COVID-19 [1,5,7].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of genes mediating the response to metformin [1,4].
Description
GO:1901558, response to metformin, is a biological process term that captures any change in a cell or organism's state or activity following exposure to metformin. Metformin is a widely prescribed biguanide for type 2 diabetes, but its effects extend far beyond glucose lowering, influencing cancer cell metabolism, inflammation, immune function, and antiviral responses [1,4,5,7]. Understanding how cells respond to metformin is therefore critical for both basic biology and therapeutic development. The term encompasses changes in movement, secretion, enzyme production, and gene expression triggered by metformin. Researchers study this process to uncover mechanisms of drug action, identify biomarkers of response, and explore repurposing opportunities in oncology, infectious diseases, and inflammatory disorders [1,4,5,7]. Because metformin engages multiple signaling nodes, including AMPK and mTOR, the response is context-dependent and cell-type specific [1,4]. This article provides a research-grade overview of GO:1901558, integrating authoritative QuickGO annotation with real PubMed literature to guide experimental design and interpretation.
response to metformin At A Glance
| GO ID | GO:1901558 |
|---|---|
| GO term | response to metformin |
| Ontology | biological_process |
| Synonym | none |
| Major function | Cellular and organismal response to metformin stimulus, including signaling, metabolic, and transcriptional changes |
| Related pathways | AMPK signaling, mTOR inhibition, mitochondrial respiration, inflammatory response |
| Key effectors | PRKAA1, PRKAA2, STK11, MTOR, ACACA, RPS6KB1 |
| Disease relevance | Type 2 diabetes, cancer, cardiovascular disease, COVID-19, tuberculosis |
| Research tools | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics |
What Is GO:1901558?
According to the Gene Ontology, GO:1901558 (response to metformin) is defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a metformin stimulus. This definition is intentionally broad, covering rapid signaling events, transcriptional reprogramming, metabolic shifts, and long-term adaptive responses. It does not specify a single molecular mechanism; instead, it serves as a parent term for more specific child processes that may involve AMPK activation, mitochondrial inhibition, or inflammatory modulation [1,4].
Why Is response to metformin Important in Cell Biology?
GO:1901558 is important because metformin is one of the most prescribed drugs worldwide, and its pleiotropic effects influence multiple diseases beyond diabetes [1,5]. Elucidating the response to metformin at the molecular level can reveal new therapeutic targets, predict patient responses, and guide drug repurposing. For researchers, this term provides a framework to systematically study how metformin alters cell behavior, from immediate signaling to long-term transcriptional changes [1,4,7].
• Metformin is first-line therapy for type 2 diabetes, and understanding its mechanism improves glycemic control.
• Epidemiological and preclinical studies suggest metformin may reduce cancer risk and progression.
• Metformin exerts anti-inflammatory effects relevant to chronic inflammatory diseases.
• It has shown potential in antiviral therapy, including against SARS-CoV-2 [3,7].
• Metformin modulates immune responses, supporting its use as adjunctive therapy in tuberculosis.
• The response to metformin involves AMPK-dependent and independent pathways, offering diverse research targets [1,4].
• Genetic variation in metformin-responsive genes can affect drug efficacy and toxicity.
• Studying GO:1901558 aids in identifying biomarkers for metformin response in clinical settings.
• Metformin's effects on mitochondrial function link it to aging and metabolic disorders.
• CRISPR screens can uncover novel genes regulating the response to metformin [1,4].
What Happens During response to metformin?
Metformin uptake and mitochondrial inhibition
In simple terms: Metformin enters cells and mildly blocks mitochondria, the cell's power plants.
Metformin is transported into cells primarily via organic cation transporters (OCTs) and then accumulates in mitochondria, where it inhibits complex I of the electron transport chain. This inhibition reduces ATP production and increases AMP levels, leading to activation of AMP-activated protein kinase (AMPK). The mitochondrial effects are considered a primary event in the cellular response to metformin, triggering downstream metabolic adaptations [1,4].
AMPK activation and energy stress response
In simple terms: Low energy triggers AMPK, a master switch that restores energy balance.
The increase in AMP/ATP ratio activates AMPK through phosphorylation by upstream kinases, notably LKB1 (STK11). Activated AMPK phosphorylates key substrates such as acetyl-CoA carboxylase (ACC) and inhibits mTORC1 signaling, thereby reducing anabolic processes and promoting catabolic pathways to restore energy homeostasis [1,4]. This AMPK-dependent arm is central to many metformin effects, including inhibition of cell growth and proliferation.
Inhibition of mTOR and protein synthesis
In simple terms: Metformin puts the brakes on cell growth by shutting down mTOR.
Metformin indirectly inhibits mTORC1 via AMPK activation and possibly through other mechanisms. mTORC1 inhibition leads to reduced phosphorylation of S6K1 and 4E-BP1, decreasing protein synthesis and cell proliferation. This effect contributes to metformin's anti-cancer and anti-aging properties [1,5].
Modulation of inflammatory and immune responses
In simple terms: Metformin can calm inflammation and change immune cell behavior.
Metformin influences inflammatory signaling pathways, including NF-kB and NLRP3 inflammasome, reducing production of pro-inflammatory cytokines. It also affects immune cell metabolism and function, which may explain its benefits in infectious diseases and autoimmune conditions [4,8]. These immunomodulatory effects are part of the broader response to metformin [4,8].
Transcriptional and metabolic reprogramming
In simple terms: Cells change which genes are turned on or off in response to metformin.
Prolonged metformin exposure leads to changes in gene expression, including upregulation of genes involved in fatty acid oxidation and downregulation of lipogenic genes. Metformin also alters cellular metabolism, such as increasing glucose uptake and lactate production in some contexts. These transcriptional and metabolic shifts are integral to the long-term response to metformin [1,4].
Key Genes Involved in GO:1901558 response to metformin
The following genes and proteins are central to the cellular response to metformin, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRKAA1 | Catalytic subunit of AMPK, senses AMP/ATP | Key mediator of metformin-induced energy stress responses |
| PRKAA2 | Catalytic subunit of AMPK, expressed in liver and muscle | Important for metformin effects on glucose metabolism |
| STK11 | Upstream kinase that phosphorylates and activates AMPK | Loss reduces metformin sensitivity; linked to Peutz-Jeghers syndrome |
| MTOR | Central regulator of cell growth and protein synthesis | Inhibited by metformin via AMPK, affecting proliferation |
| ACACA | Acetyl-CoA carboxylase, rate-limiting for fatty acid synthesis | Phosphorylated by AMPK, leading to reduced lipogenesis |
| RPS6KB1 | S6 kinase 1, downstream of mTORC1 | Phosphorylation decreases with metformin, reflecting mTOR inhibition |
| EIF4EBP1 | Repressor of translation initiation | Dephosphorylated upon mTOR inhibition by metformin |
| NFKB1 | Transcription factor regulating inflammation | Metformin inhibits NF-kB signaling, reducing cytokine production |
| NLRP3 | Inflammasome component | Metformin inhibits NLRP3 inflammasome activation |
| TNF | Pro-inflammatory cytokine | Metformin reduces TNF levels in inflammatory models |
| IL6 | Pro-inflammatory cytokine | Metformin decreases IL-6 production |
| SLC22A1 | Organic cation transporter 1, mediates metformin uptake | Genetic variants affect metformin pharmacokinetics |
| SLC22A2 | Organic cation transporter 2, renal metformin transport | Polymorphisms influence metformin clearance |
| SLC47A1 | Multidrug and toxin extrusion 1, metformin efflux | Variants associated with metformin response |
| PPARGC1A | PGC-1alpha, regulator of mitochondrial biogenesis | Metformin may modulate its activity |
| TP53 | Tumor suppressor, responds to metabolic stress | Metformin effects on p53-dependent apoptosis |
| CDKN1A | p21, cell cycle inhibitor | Metformin can induce p21, causing cell cycle arrest |
| MKI67 | Marker of proliferation | Metformin reduces Ki-67 expression in tumors |
How Is response to metformin Regulated?
The response to metformin is regulated at multiple levels. Upstream, the AMPK pathway is controlled by LKB1 (STK11) and calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2). Metformin also affects mTOR signaling through AMPK-dependent and independent mechanisms. Additionally, metformin can modulate the integrated stress response (ISR) and autophagy, which feedback on cellular metabolism [1,4]. Inflammatory pathways, such as NF-kB, are also regulated by metformin, contributing to its immunomodulatory effects. The expression of organic cation transporters (OCTs) determines intracellular metformin levels and thus the intensity of the response.
response to metformin and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STK11 | Peutz-Jeghers syndrome, cancer predisposition | Knockout in cancer cell lines to test metformin sensitivity |
| PRKAA1 | Type 2 diabetes, metabolic syndrome | Point mutation to mimic AMPK activation/inhibition |
| SLC22A1 | Altered metformin pharmacokinetics | Knockout in hepatocytes to study uptake |
| NFKB1 | Inflammatory diseases | Knockout in macrophages to assess cytokine production |
| NLRP3 | Autoinflammatory syndromes | Knock-in of gain-of-function mutation to test metformin inhibition |
Metformin and cancer
Metformin has been associated with reduced cancer risk and improved outcomes in some epidemiological studies. At the cellular level, metformin inhibits proliferation, induces apoptosis, and reduces metastasis through AMPK-dependent and independent mechanisms. The response to metformin in cancer cells involves mTOR inhibition, cell cycle arrest, and metabolic reprogramming. These effects are being explored in clinical trials for various malignancies, including resistant hematological malignancies.
Metformin and inflammatory diseases
Chronic inflammation is a hallmark of many diseases, and metformin exerts anti-inflammatory effects by inhibiting NF-kB and NLRP3 inflammasome. These actions may benefit conditions such as atherosclerosis, inflammatory bowel disease, and sepsis. The immunomodulatory effects of metformin also support its potential use in tuberculosis as adjunctive therapy.
Metformin and viral infections
Metformin has shown antiviral properties, including against SARS-CoV-2, potentially through AMPK activation and modulation of immune responses [3,7]. Observational studies suggest that metformin use is associated with reduced COVID-19 severity, though randomized trial results are mixed. The response to metformin in infected cells involves metabolic and inflammatory pathways that may limit viral replication [3,7].
Metformin and metabolic disorders
In type 2 diabetes, metformin improves glycemic control by reducing hepatic glucose production and increasing insulin sensitivity. The molecular response includes AMPK activation, inhibition of gluconeogenic gene expression, and enhanced glucose uptake in muscle. Genetic variants in transporters and AMPK subunits can influence therapeutic response.
From response to metformin-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does AMPK mediate metformin's effects on glucose production? | PRKAA1/PRKAA2 double knockout hepatocytes |
| What is the role of LKB1 in metformin response? | STK11 knockout cancer cell lines |
| How do SLC22A1 variants affect metformin uptake? | Point mutation knock-in in HEK293 cells |
| Does metformin inhibit NLRP3 inflammasome? | NLRP3 knockout macrophages |
| Can metformin reduce tumor growth via mTOR inhibition? | MTOR knockout or knockdown in xenograft models |
| What genes are essential for metformin-induced autophagy? | Genome-wide CRISPR knockout screen |
How to Study the response to metformin Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Changes in gene expression | Identify metformin-responsive transcriptional programs |
| Phosphoproteomics | Changes in protein phosphorylation | Map AMPK/mTOR signaling after metformin |
| Seahorse assay | Mitochondrial respiration and glycolysis | Assess metabolic effects of metformin |
| Western blot | Protein levels and phosphorylation | Validate AMPK activation and mTOR inhibition |
| CRISPR knockout screen | Gene essentiality for metformin response | Discover novel regulators |
| qPCR | mRNA levels of target genes | Confirm transcriptional changes |
| Immunofluorescence | Protein localization and expression | Visualize pathway activation in situ |
| Metabolomics | Small molecule metabolite levels | Profile metabolic shifts induced by metformin |
Transcriptomics (RNA-seq)
RNA sequencing can reveal global changes in gene expression following metformin treatment, identifying pathways and gene signatures associated with GO:1901558. This method is useful for discovering novel metformin-responsive genes and comparing responses across cell types.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in protein abundance and phosphorylation status after metformin exposure, particularly in AMPK and mTOR pathways. Phosphoproteomics is especially valuable for mapping signaling events downstream of AMPK activation.
Metabolic assays
Seahorse extracellular flux analysis and metabolite profiling measure mitochondrial respiration, glycolysis, and ATP levels, providing functional readouts of metformin's effects on cellular metabolism. These assays are critical for understanding the bioenergetic response to metformin.
CRISPR screens
Genome-wide CRISPR knockout or activation screens can identify genes that modulate sensitivity or resistance to metformin, uncovering novel regulators of GO:1901558. Such screens are powerful for unbiased discovery of metformin response pathways.
How CRISPR Can Be Used to Study GO:1901558 response to metformin
Knockout
CRISPR knockout of candidate genes such as PRKAA1, STK11, or SLC22A1 allows researchers to test their requirement for metformin-induced phenotypes. For example, knocking out STK11 in cancer cells reduces AMPK activation and metformin sensitivity. Knockout models are essential for establishing causality in the response to metformin.
Point Mutation
Introducing specific point mutations (e.g., in PRKAA1 to mimic phosphorylation or in SLC22A1 to alter transport activity) can dissect the precise molecular mechanisms of metformin response. Point mutation knock-in models are valuable for studying drug transporter polymorphisms and kinase activation.
Knock-in
Knock-in of tagged versions of proteins (e.g., GFP-AMPK) enables real-time imaging and interaction studies in response to metformin. Knock-in of disease-associated variants can model inter-individual differences in metformin response.
Overexpression
Overexpression of genes such as STK11 or PRKAA1 can enhance metformin sensitivity and amplify downstream signaling, helping to identify pathway components. Conversely, overexpression of dominant-negative mutants can block the response. Overexpression models are useful for gain-of-function studies in metformin research.
How EDITGENE Supports response to metformin Research
Researchers studying response to metformin-related genes often need to determine whether a candidate gene is causally involved in the cellular response to the drug. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes implicated in GO:1901558.
Contact EDITGENE today to design your custom CRISPR model for response to metformin research.
Frequently Asked Questions About response to metformin
What is GO:1901558?
GO:1901558 is the Gene Ontology term for 'response to metformin', defined as any process that results in a change in state or activity of a cell or organism as a result of a metformin stimulus.
What genes are involved in response to metformin?
Key genes include PRKAA1, PRKAA2, STK11, MTOR, ACACA, RPS6KB1, and SLC22A1, among others.
How does metformin activate AMPK?
Metformin inhibits mitochondrial complex I, increasing AMP/ATP ratio, which activates AMPK via LKB1-dependent phosphorylation.
What diseases are linked to metformin response?
Metformin response is relevant to type 2 diabetes, cancer, cardiovascular disease, COVID-19, and tuberculosis [1,3,5,7,8].
Can CRISPR be used to study metformin response?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect genes involved in GO:1901558.
What are the main signaling pathways in response to metformin?
The AMPK/mTOR pathway is central, along with inflammatory signaling (NF-kB, NLRP3) and metabolic reprogramming [1,4].
How does metformin affect cancer cells?
Metformin inhibits proliferation, induces apoptosis, and reduces metastasis, partly through AMPK activation and mTOR inhibition.
Is metformin effective against COVID-19?
Observational studies suggest metformin may reduce COVID-19 severity, but randomized trial results are mixed.
What is the role of SLC22A1 in metformin response?
SLC22A1 encodes OCT1, which mediates metformin uptake into cells; genetic variants affect drug response.
How can I study metformin response in my lab?
Use CRISPR-engineered cell models, RNA-seq, proteomics, and metabolic assays to interrogate GO:1901558.
Conclusion
GO:1901558 (response to metformin) encompasses a complex network of cellular and organismal changes triggered by metformin, with AMPK/mTOR signaling, metabolic reprogramming, and immunomodulation as key components [1,4]. Understanding this process is essential for optimizing metformin therapy and exploring new indications in cancer, infectious diseases, and inflammatory disorders [1,5,7,8]. CRISPR-based models and multi-omics approaches provide powerful tools to dissect the underlying mechanisms and identify novel therapeutic targets.
References
- 1. Pernicova I et al.. 2014. Metformin--mode of action and clinical implications for diabetes and cancer.. Nat Rev Endocrinol 10(3):143-56 PMID: 24393785
- 3. Halabitska I et al.. 2024. Metformin in Antiviral Therapy: Evidence and Perspectives.. Viruses 16(12) PMID: 39772244
- 4. Bharath LP et al.. 2021. The intersection of metformin and inflammation.. Am J Physiol Cell Physiol 320(5):C873-C879 PMID: 33689478
- 5. Vallianou NG et al.. 2013. Metformin and cancer.. Rev Diabet Stud 10(4):228-35 PMID: 24841876
- 6. Paz GS et al.. 2024. Metformin as a therapeutic tool for resistant hematological malignancies: a literature review.. Chin Clin Oncol 13(3):39 PMID: 38859606
- 7. Wiernsperger N et al.. 2022. Protection by metformin against severe Covid-19: An in-depth mechanistic analysis.. Diabetes Metab 48(4):101359 PMID: 35662580
- 8. Sutter A et al.. 2024. Metformin has immunomodulatory effects which support its potential use as adjunctive therapy in tuberculosis.. Indian J Tuberc 71(1):89-95 PMID: 38296396
